Neuromyelitis Optica Spectrum Disorder (NMOSD)

Infection in NMOSD: Analyzing the patterns of infection in the SAkura studies, satralizumab▼ post-marketing data, and NMOSD US PharMetrics claims data

This analysis aimed to evaluate the pattern of infection following long-term satralizumab▼ treatment in the SAkura studies, and to compare the post-marketing (PM) experience to real-world data (RWD) from a US claims database (where >99% of patients were not receiving satralizumab▼).

Long-term efficacy of satralizumab▼ in patients with AQP4-IgG+ NMOSD: Updated analysis from the open-label SAkuraMoon study

The long-term efficacy of satralizumab▼ was evaluated in patients with AQP4-IgG-seropositive NMOSD with up to 8.9 years of treatment (median exposure: ~5.9 years), in the open-label SAkuraMoon study (NCT04660539).

Burdens of Neuromyelitis Optica Spectrum Disorder: Real-World Perspectives From Caregivers

The burden of care for caregivers of individuals with neuromyelitis optica spectrum disorders (NMOSD) has not been well characterized. This study explored experiences of NMOSD caregivers and potential impacts of caregiving on their own health and well-being. Outcomes for NMOSD caregivers were compared with those in the US general population, including non-caregivers, non-NMOSD/non-multiple sclerosis (MS) caregivers and MS caregivers.

Satralizumab▼ treatment in adults with AQP4-IgG–seropositive neuromyelitis optica spectrum disorder: a retrospective case series

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune neuroinflammatory disease. Satralizumab▼ is a humanised monoclonal recycling antibody against the interleukin 6 receptor with demonstrated safety and efficacy in patients with NMOSD in 2 randomized, placebo-controlled Phase III clinical trials (SAkuraSky [NCT02028884] and SAkuraStar [NCT02073279]). The objective of this real-world, retrospective case series was to describe the experience with satralizumab▼ in adults with AQP4-IgG+ NMOSD in clinical practice.

Brain exchange: Not all it seems? Following the clues in neuroimmunology

This session will open with a brief case of clinical demyelination and a discussion of the diffential diagnosis. The presenters will then co-lead a discussion on the underlying mehanism of disease (e.g. pathologic auto-antibodies) and the links to the diagnostic testing and interpretation. This session will primarily discuss NMOSD and MOGAD.

Watch: Not All it Seems? Following the Clues in Neuroimmunology

Watch this brain exchange, which explores MS, NMOSD, and MOGAD, with a focus on clinical demyelination, the underlying mechanisms of disease, and how they link to diagnostic testing and interpretation.

External site

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Ask a question or share feedback